WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004026871) NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/026871    International Application No.:    PCT/US2003/026297
Publication Date: 01.04.2004 International Filing Date: 16.09.2003
IPC:
C07D 471/04 (2006.01), C07D 519/00 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US) (For All Designated States Except US).
BEIGHT, Douglas, Wade [US/US]; (US) (For US Only).
BONJOUKLIAN, Rosanne [US/US]; (US) (For US Only).
LIAO, Junkai [US/US]; (US) (For US Only).
MCMILLEN, William, Thomas [US/US]; (US) (For US Only).
PARKHURST, Brandon, Lee [US/US]; (US) (For US Only).
SAWYER, Jason, Scott [US/US]; (US) (For US Only).
YINGLING, Jonathan, Michael [US/US]; (US) (For US Only).
YORK, Jeremy, Schulenburg [US/US]; (US) (For US Only)
Inventors: BEIGHT, Douglas, Wade; (US).
BONJOUKLIAN, Rosanne; (US).
LIAO, Junkai; (US).
MCMILLEN, William, Thomas; (US).
PARKHURST, Brandon, Lee; (US).
SAWYER, Jason, Scott; (US).
YINGLING, Jonathan, Michael; (US).
YORK, Jeremy, Schulenburg; (US)
Agent: SAYLES, Michael, J.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US)
Priority Data:
60/411,560 17.09.2002 US
Title (EN) NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS
(FR) DERIVES DE PYRAZOLOPYRIDINE TENANT LIEU D'AGENTS PHARMACEUTIQUES
Abstract: front page image
(EN)Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.
(FR)L'invention concerne des dérivés de pyrazolopyridine et leur utilisation comme agents pharmaceutiques, en particulier comme inhibiteurs de transduction de signal de TGF-bêta dans le traitement du cancer et d'autres maladies sur lesquelles influe le TGF bêta.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)